387 related articles for article (PubMed ID: 33323544)
1. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
2. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
3. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
4. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
[TBL] [Abstract][Full Text] [Related]
6. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
7. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
11. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
12. Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database.
Jin K; Qiu S; Jin D; Zhou X; Zheng X; Li J; Liao X; Yang L; Wei Q
Aging (Albany NY); 2021 Jan; 13(2):1859-1871. PubMed ID: 33465047
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
[TBL] [Abstract][Full Text] [Related]
14. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer.
Zhang X; Zhao H; Shi X; Jia X; Yang Y
Aging (Albany NY); 2020 Dec; 12(24):26095-26120. PubMed ID: 33401247
[TBL] [Abstract][Full Text] [Related]
16. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
17. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
18. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
19. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
20. Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia.
Dao FT; Wang J; Yang L; Qin YZ
Sci Rep; 2021 Mar; 11(1):4856. PubMed ID: 33649342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]